Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Akebia Therapeutics	Verastem	Fortress Biotech	Forte Biosciences	89bio
Symbol	NASDAQ:AKBA	NASDAQ:VSTM	NASDAQ:FBIO	NASDAQ:FBRX	NASDAQ:ETNB
Price Information
Current Price	$3.05	$2.96	$4.06	$34.48	$23.99
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.8	1.1	1.6	1.7	1.6
Analysis Score	3.3	1.5	4.5	3.5	3.6
Community Score	2.7	2.6	2.7	3.5	2.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.8	0.0	0.8	1.7
Earnings & Valuation Score	1.3	0.6	0.6	0.6	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$9.63	$3.00	$10.80	$82.00	$61.88
% Upside from Price Target	215.57% upside	1.35% upside	166.01% upside	137.82% upside	157.92% upside
Trade Information
Market Cap	$487.72 million	$503.84 million	$394.85 million	$467.82 million	$499.47 million
Beta	2.11	0.72	2.43	0.23	N/A
Average Volume	5,738,887	2,717,986	1,601,775	176,126	140,491
Sales & Book Value
Annual Revenue	$335 million	$17.46 million	$36.63 million	$40,000.00	N/A
Price / Sales	1.46	29.10	10.78	11,644.76	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$3.32 per share	$0.09 per share	$1.02 per share	$6.81 per share	$6.92 per share
Price / Book	0.92	32.89	3.98	5.06	N/A
Profitability
Net Income	$-279,660,000.00	$-149,210,000.00	$-39,960,000.00	$-63,520,000.00	$-57,420,000.00
EPS	($1.63)	($2.00)	($0.73)	($40.33)	($24.49)
Trailing P/E Ratio	N/A	N/A	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-126.86%	-590.19%	-131.98%	N/A	N/A
Return on Equity (ROE)	-68.51%	-189.37%	-44.08%	-417.87%	-49.56%
Return on Assets (ROA)	-34.01%	-67.69%	-19.06%	-248.28%	-46.52%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.24%	0.45%	0.29%	N/A	N/A
Current Ratio	2.15%	5.02%	6.38%	8.97%	23.61%
Quick Ratio	1.67%	4.80%	6.35%	8.97%	23.61%
Ownership Information
Institutional Ownership Percentage	68.98%	42.15%	32.13%	53.03%	80.63%
Insider Ownership Percentage	2.55%	2.90%	29.50%	10.90%	18.10%
Miscellaneous
Employees	379	48	111	9	26
Shares Outstanding	159.91 million	171.67 million	97.25 million	13.51 million	20.04 million
Next Earnings Date	5/10/2021 (Confirmed)	5/6/2021 (Estimated)	5/10/2021 (Estimated)	5/10/2021 (Confirmed)	5/12/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Not Optionable	Not Optionable

Source	Headline
	89bio to Present at Upcoming Investor Conferences - GlobeNewswire globenewswire.com - May 5 at 8:28 AM
	89bio, Inc. (NASDAQ:ETNB) Short Interest Up 20.5% in April americanbankingnews.com - May 4 at 4:44 PM
	89bio (NASDAQ:ETNB) Stock Price Up 4.3% americanbankingnews.com - April 27 at 12:54 PM
	89bio (NASDAQ:ETNB) Earns Overweight Rating from Analysts at Cantor Fitzgerald americanbankingnews.com - April 27 at 9:12 AM
	Insider Selling: 89bio, Inc. (NASDAQ:ETNB) Director Sells 850 Shares of Stock americanbankingnews.com - April 23 at 11:04 PM
	Brokers Offer Predictions for 89bio, Inc.'s FY2021 Earnings (NASDAQ:ETNB) americanbankingnews.com - April 23 at 8:22 AM
	89bio (NASDAQ:ETNB) Shares Down 6.3% americanbankingnews.com - April 22 at 1:36 PM
	Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2021 - Benzinga benzinga.com - April 21 at 1:52 PM
	Is it Time to Dump 89bio Inc (ETNB) Stock After it Is Up 15.35% in a Week? - InvestorsObserver investorsobserver.com - April 21 at 1:52 PM
	89bio could close the valuation gap with Akero by end of 2021: Cantor - Seeking Alpha seekingalpha.com - April 21 at 1:52 PM
	89bio (NASDAQ:ETNB) Shares Gap Up to $25.81 americanbankingnews.com - April 21 at 10:36 AM
	Cantor Fitzgerald Begins Coverage on 89bio (NASDAQ:ETNB) americanbankingnews.com - April 21 at 8:28 AM
	Ryan Martins Sells 10,000 Shares of 89bio, Inc. (NASDAQ:ETNB) Stock americanbankingnews.com - April 20 at 7:42 PM
	89bio (NASDAQ:ETNB) Stock Price Up 3% americanbankingnews.com - April 20 at 1:58 PM
	89bio, Inc. (NASDAQ:ETNB) Insider Ram Waisbourd Sells 7,000 Shares americanbankingnews.com - April 19 at 7:46 PM
	89bio (NASDAQ:ETNB) Is In A Good Position To Deliver On Growth Plans - Nasdaq nasdaq.com - April 15 at 5:11 PM
	89bio, Inc. (NASDAQ:ETNB) Given Average Recommendation of "Buy" by Analysts americanbankingnews.com - April 15 at 5:04 PM
	Health Archives - Market Primes marketprimes.com - April 14 at 7:58 AM
	Clinical Catch-Up: April 5-9 - BioSpace biospace.com - April 13 at 12:38 AM
	Leerink Partners Sticks to Their Buy Rating for 89bio (ETNB) - Smarter Analyst smarteranalyst.com - April 9 at 12:19 PM
	89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH - Yahoo Finance finance.yahoo.com - April 6 at 7:50 PM
	Do Traders Think 89bio Inc (ETNB) Can Keep Climbing Monday? - InvestorsObserver investorsobserver.com - April 5 at 11:01 PM
	89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH - GlobeNewswire globenewswire.com - April 5 at 1:00 PM
	89bio Announces Plans for Phase 2b (ENLIVEN) Trial in NASH finance.yahoo.com - April 5 at 1:00 PM
	Implied VHT Analyst Target Price: $260 - Nasdaq nasdaq.com - April 1 at 2:25 PM

Date	Company	Brokerage	Action
3/15/2021	Akebia Therapeutics	HC Wainwright	Lower Price Target
3/15/2021	Akebia Therapeutics	Cantor Fitzgerald	Initiated Coverage
1/29/2021	Akebia Therapeutics	JPMorgan Chase & Co.	Downgrade
9/4/2020	Akebia Therapeutics	Morgan Stanley	Lower Price Target
9/4/2020	Akebia Therapeutics	BTIG Research	Lower Price Target
9/4/2020	Akebia Therapeutics	Mizuho	Lower Price Target
8/11/2020	Akebia Therapeutics	Needham & Company LLC	Initiated Coverage
5/6/2020	Akebia Therapeutics	Royal Bank of Canada	Boost Price Target
8/2/2019	Verastem	B. Riley	Set Price Target
5/14/2019	Verastem	Roth Capital	Lower Price Target
5/10/2019	Verastem	Raymond James	Downgrade
7/27/2018	Verastem	Seaport Global Securities	Set Price Target
2/17/2021	Fortress Biotech	Dawson James	Boost Price Target
10/2/2020	Fortress Biotech	Benchmark	Initiated Coverage
5/21/2018	Fortress Biotech	JMP Securities	Set Price Target
4/1/2021	Forte Biosciences	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage
3/26/2021	Forte Biosciences	(FBRC)	Initiated Coverage
3/23/2021	Forte Biosciences	Chardan Capital	Lower Price Target
8/28/2020	Forte Biosciences	Brookline Capital Management	Initiated Coverage
8/25/2020	Forte Biosciences	Truist Securiti	Initiated Coverage
6/22/2020	Forte Biosciences	LADENBURG THALM/SH SH	Initiated Coverage
3/29/2021	89bio	SVB Leerink	Boost Price Target
3/18/2021	89bio	Oppenheimer	Reiterated Rating
9/25/2020	89bio	Bank of America	Upgrade
7/30/2020	89bio	Piper Sandler	Initiated Coverage

(Data available from 5/5/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources